Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C23H31FO6
CAS Number:
Molecular Weight:
422.49
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
208-180-4
MDL number:
Product Name
Fludrocortisone acetate, ≥98%
biological source
synthetic
Quality Level
sterility
non-sterile
assay
≥98%
form
powder
solubility
acetone: 50 mg/mL, clear, colorless to light yellow
shipped in
ambient
storage temp.
room temp
SMILES string
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C
InChI
1S/C23H31FO6/c1-13(25)30-12-19(28)22(29)9-7-16-17-5-4-14-10-15(26)6-8-20(14,2)23(17,24)18(27)11-21(16,22)3/h10,16-18,27,29H,4-9,11-12H2,1-3H3/t16-,17-,18-,20-,21-,22-,23-/m0/s1
InChI key
SYWHXTATXSMDSB-GSLJADNHSA-N
Gene Information
human ... NR3C2(4306)
General description
Fludrocortisone acetate is secreted by adrenal cortex. It increases the reabsorption of sodium and secretion of potassium and hydrogen. Fludrocortisone is used to treat cerebral salt wasting syndrome and adrenal insufficiency. Fludrocortisone improves the sensitivity of blood vessels to catecholamines and increases the blood volume.
Biochem/physiol Actions
Fludrocortisone acetate is a synthetic corticosteroid with more mineralocorticoid than glucocorticoid activity.
Still not finding the right product?
Explore all of our products under Fludrocortisone acetate
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Repr. 2
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
R Taniguchi et al.
The Tohoku journal of experimental medicine, 186(3), 215-223 (1999-05-29)
It is known that some patients with primary aldosteronism show postoperative hyperkalemia, which is due to inability of the adrenal gland to secrete sufficient amounts of aldosterone. However, hyperkalemia is generally neither severe nor prolonged, in which replacement therapy with
S Yamashiro et al.
Acta neurochirurgica, 139(10), 987-990 (1997-01-01)
This 67 year-old man experienced 3 episodes of symptomatic hyponatraemia. Radiological examination revealed a sellar lesion and the tumour was removed via the transsphenoidal route. Thereafter, he simultaneously developed intractable diabetes insipidus and serious hyponatraemia with persistent natriuresis. His level
Clinical Pharmacology Made Incredibly Easy! (2009)

